Anti-Coagulants - Laos

Laos

The projected revenue for the Anti-Coagulants market in Laos is expected to reach US$0.91m in 2024.
Furthermore, it is anticipated that the revenue will grow at an annual rate of 7.23% from 2024 to 2029, resulting in a market volume of US$1.29m by the end of 2029.
In terms of global comparison, United States is projected to generate the highest revenue in this market, amounting to US$16,740.00m in 2024.
In Laos, the demand for anti-coagulants is growing steadily due to an aging population and increasing prevalence of cardiovascular diseases.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Anti-Coagulants in Laos has been increasing steadily over the years.

Customer preferences: Patients suffering from cardiovascular diseases are the primary customers of Anti-Coagulants. As the population of Laos is aging, the incidence of cardiovascular diseases is increasing. This has led to a rise in demand for Anti-Coagulants in the country.

Trends in the market: The Anti-Coagulants market in Laos is witnessing a shift towards the use of newer oral anticoagulants (NOACs) from traditional anticoagulants such as warfarin. NOACs are more convenient to use and do not require regular blood tests. They are also associated with lower risks of bleeding and stroke. The increasing adoption of NOACs is a major trend in the Anti-Coagulants market in Laos.

Local special circumstances: Laos is a landlocked country in Southeast Asia. The healthcare infrastructure in the country is not well-developed, especially in the rural areas. This has led to a lack of access to healthcare services for a significant proportion of the population. The lack of awareness about the benefits of Anti-Coagulants among the general population is also a challenge in the market.

Underlying macroeconomic factors: The economic growth in Laos has been robust in recent years. The country has been focusing on developing its infrastructure and attracting foreign investments. This has led to an increase in the disposable income of the population. As a result, more people are able to afford healthcare services, including Anti-Coagulants. The government of Laos has also been investing in the healthcare sector, which is expected to drive the growth of the Anti-Coagulants market in the country.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.